207 related articles for article (PubMed ID: 9829739)
1. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.
Cassidy J; Dirix L; Bissett D; Reigner B; Griffin T; Allman D; Osterwalder B; Van Oosterom AT
Clin Cancer Res; 1998 Nov; 4(11):2755-61. PubMed ID: 9829739
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Mackean M; Planting A; Twelves C; Schellens J; Allman D; Osterwalder B; Reigner B; Griffin T; Kaye S; Verweij J
J Clin Oncol; 1998 Sep; 16(9):2977-85. PubMed ID: 9738566
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Fakih MG; Creaven PJ; Ramnath N; Trump D; Javle M; Strychor S; Repinski TV; Zamboni BA; Schwarz JK; French RA; Zamboni WC
Clin Cancer Res; 2005 Aug; 11(16):5942-9. PubMed ID: 16115937
[TBL] [Abstract][Full Text] [Related]
6. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
[TBL] [Abstract][Full Text] [Related]
8. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients.
Nemunaitis J; Adams N; Cunningham C; Senzer N; Graham S; Barrera D; Nugent J; Stewart C
J Oncol Manag; 2005; 14(3):77-90. PubMed ID: 16161645
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
11. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
Fakih MG; Rajput A; Yang GY; Pendyala L; Toth K; Smith JL; Lawrence DD; Rustum YM
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1462-70. PubMed ID: 16750332
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Villalona-Calero MA; Blum JL; Jones SE; Diab S; Elledge R; Khoury P; Von Hoff D; Kraynak M; Moczygemba J; Kromelis P; Griffin T; Rowinsky EK
Ann Oncol; 2001 May; 12(5):605-14. PubMed ID: 11432617
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; Semiond D; deJonge MJ; Eskens FA; ter Steeg J; Selleslach J; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
J Clin Oncol; 2005 Feb; 23(4):889-98. PubMed ID: 15681535
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
[TBL] [Abstract][Full Text] [Related]
15. A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
Michaelson MD; Ryan DP; Fuchs CS; Supko JG; Garcia-Carbonero R; Paul Eder J; Clark JW
Cancer; 2003 Jan; 97(1):148-54. PubMed ID: 12491516
[TBL] [Abstract][Full Text] [Related]
16. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Pronk LC; Vasey P; Sparreboom A; Reigner B; Planting AS; Gordon RJ; Osterwalder B; Verweij J; Twelves C
Br J Cancer; 2000 Jul; 83(1):22-9. PubMed ID: 10883663
[TBL] [Abstract][Full Text] [Related]
18. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
Saif MW; Sarantopoulos J; Patnaik A; Tolcher AW; Takimoto C; Beeram M
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1565-73. PubMed ID: 21547572
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
Díaz-Rubio E; Evans TR; Tabemero J; Cassidy J; Sastre J; Eatock M; Bisset D; Regueiro P; Baselga J
Ann Oncol; 2002 Apr; 13(4):558-65. PubMed ID: 12056706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]